Melanotan II dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of Melanotan II actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
Why there is no units chart for Melanotan II
Every dose quoted in studies of Melanotan II is given per kilogram of body weight, and none is an absolute quantity. A chart of syringe units needs a fixed mass to work from, so there is nothing honest to put in one.
The obvious move — multiply a per-kilogram figure by a body weight — is the one thing that must not be done here. Most of these figures come from rats or mice, and dose does not scale between species by arithmetic: surface area, metabolic rate and clearance all differ, which is why interspecies conversion is a calculation with published factors and assumptions rather than a multiplication. A number produced that way would look like a dose and carry none of the evidence a dose needs.
The calculator above still works. Give it the vial and the mass you intend to draw and it returns the volume and the units. What it cannot do, for this compound, is tell you what that mass should be, because no study in this ledger states one.
Doses in published studies of Melanotan II
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. 3 of 4 come from human studies; the rest are animal or laboratory work.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Human clinical trial | In the phase 1 pilot, three men received 0.01 mg/kg subcutaneously on alternate weekdays for two weeks, escalated to 0.025 or 0.03 mg/kg. | pmid-8637402 |
| Human clinical trial | Men with erectile dysfunction received 0.025 mg/kg subcutaneously, twice each for drug and placebo. | pmid-11018622 |
| Human clinical trial | The 1998 trial in ten men with psychogenic erectile dysfunction used the same 0.025 mg/kg dose. | pmid-9679884 |
| Animal, preclinical | In mice, 120 micrograms per kilogram a day by intravenous infusion for seven days reduced food intake and transiently raised blood pressure and heart rate. | pmid-29351428 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- 0.01 to 0.03 mg/kg subcutaneous in the phase 1 pilot; 0.025 mg/kg in the erection trials. pmid-8637402
- 120 micrograms per kilogram a day intravenous in mice. pmid-29351428
Escalation schedules used in studies
Where a trial raised the dose over time rather than starting at the target, this is what it did. The starting dose is often the part that decides tolerability, which is why it is reported here and not only the dose the trial finished on.
- The phase 1 pilot escalated by 0.005 mg/kg steps from 0.01 mg/kg to 0.025 or 0.03 mg/kg over two weeks. pmid-8637402
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of Melanotan II actually ran for.
- Two weeks of alternate-day dosing in the pilot; single doses with six hours of monitoring in the erection trials. pmid-8637402
- The 2026 case report followed a user who injected for 64 days, then for three months after stopping. pmid-41752902
How Melanotan II was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Randomized controlled trial, humans, 2000: administration by subcutaneous route reported. Melanotan II (0.025 mg/kg) and vehicle were each administered twice by subcutaneous injection; real-time RigiScan monitoring and a visual analog were used to quantify the erections during a 6-hour period. pmid-11018622
- Phase 1 clinical trial, humans, 1996: administration by subcutaneous route reported. Subcutaneous injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. pmid-8637402
- Case report, humans, 2026: administration by oral route reported. To date, there is a lack of published data specifically addressing the timeline for resolution of oral pigmentation associated with Melanotan II use, making this case a valuable contribution to the limited existing literature on the subject. pmid-41752902
- Case report, humans, 2025: administration by intranasal route reported. The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. pmid-40210573
- Case report, humans, 2021: administration by subcutaneous route reported. We describe in this case report a patient presenting with acute ischemic priapism after subcutaneous injection of melanotan II. pmid-33460908
- Nasal sprays have never been studied; the one published account is the 2025 mucosal melanoma case report.
Questions people ask
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the Melanotan II record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. A dose that appeared in a trial appeared under supervision, with monitoring, in people selected for that trial.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures